EGF and colorectal carcinoma: The 5-year survival of CRC patients showing disease recurrence or being metastatic at diagnosis falls from 80–90% to 10–20% despite development of novel chemotherapeutics or the introduction of targeted therapies against VEGF and EGF signaling [62].